Skip to main content
Log in

Transdermal estroprogestins versus transdermal estrogen plus oral dihydrogesterone replacement in menopause

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

We studied 18 early (6 to 36 months) postmenopausal patients with a mean age of 51 years (47–53), who had never undergone hormone replacement therapy before and had no contraindications to hormone replacement. All cases of menopause were spontaneous. The treatment consisted in the continuous transdermal administration of 17-ß-estradiol (50 μg/daily) by skin patch to be replaced every 84 hours. The patients were further treated with a two-week progestogen administration every fortnight. This consisted of transdermal norethisterone acetate (0.25 mg/daily) combined with estradiol in the same patch in the first year, and oral dihydrogesterone (10 mg/daily) in the second year, without wash-out period. Before treatment (TO), and at the 12th (T1) and 24th (T2) month we measured the body mass index, the arterial blood pressure (AP), lipoproteins, coagulation parameters and bone metabolism parameters. The systolic pressure presented mean values (±SD) equal to 128.5±10.2 mmHg (T0), 131.1±7.4 mmHg (T1), and 130.4 ±7.5 mmHg (T2). Diastolic pressure values showed mean value ranging from 85.4±8.7 mmHg (T0) to 83.9±5.3 (T1) and 83.4±5.8 mmHg (T2). The detailed analysis of values of triglycerides, HDL cholesterol, apolipoprotein A1, apolipoprotein B and coagulation parameters at different times of therapy showed no statistically significant changes. With regard to bone metabolism, no statistically significant changes from baseline values were observed in the parathormone, alkaline phosphatase, calcitonin, urinary calcium/creatinine ratio, and bone mineral content expressed by the bone density.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Henderson B.E., Ross R.K., Lobo R.A., Pike M.C., Mack T.M. Re-evaluating the role of progestogen therapy after menopause. Fertil. Steril. 49: 9S, 1988.

  2. Paganini-Hill A., Ross R.H., Henderson B.E. Postmenopausal oestrogen treatment and hearth stroke: a prospective study. Br. Med. J. 297: 519, 1988.

    Article  CAS  Google Scholar 

  3. Egeland G.M., Kuller L.H., Matthews K.A., Kelsey S.F., Cauley J., Guzick D. Hormone replacement therapy and lipoprotein changes during early menopause. Obstet. Gynecol. 76: 776, 1990.

    Article  PubMed  CAS  Google Scholar 

  4. Sullivan J.M., Van Der Zwaag R., Lemp G.F., Hughes J.P., Moddok V., Kroetz F.W., Ramanthan K.B., Mirvis D.M. Estrogen replacement therapy and coronary artery disease: effect on survival in postmenopausal women. Arch. Intern. Med. 150: 2557, 1990.

    Article  PubMed  CAS  Google Scholar 

  5. Sitruk-Ware R., Ibarra De Palcios P. Oestrogen replacement therapy and cardiovascular disease in postmenopausal women. Maturitas 11: 259, 1989.

    Article  PubMed  CAS  Google Scholar 

  6. Judd H.L., Meldrum D.R., Deftos L.J., Henderson B.E. Estrogen replacement therapy: indications and complications. Ann. Intern. Med. 98: 195, 1983.

    Article  PubMed  CAS  Google Scholar 

  7. Drapier-Faure E. Reflexions sur le traitment hormonal de la menopause en 1990. Gynécologie 41: 273, 1990.

    Google Scholar 

  8. Gambreil R.D. Jr. The prevention of endometrial cancer in postmenopausal women with progestogens. Maturitas 1: 107, 1978

    Article  Google Scholar 

  9. Whitehead M., Townsend P.T., Pryse-Davies J., Ryder TA, King R.J.B. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N. Engl. J. Med. 305: 1599, 1981.

    Article  PubMed  CAS  Google Scholar 

  10. Huovinen K., Autio S., Kaprio J. Peroral lynestrenol and arterial disease in mentally retarded women. Acta Obstet. Gynecol. Scand. 67: 211, 1988.

    Article  PubMed  CAS  Google Scholar 

  11. Ottosson U.B., Johansson B.G., von Shoultz B. Subfractions of high density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogen and natural progesterone. Am. J. Obstet. Gynecol. 151: 746, 1985.

    Article  PubMed  CAS  Google Scholar 

  12. Da Cleyn K., Buytaert P., Delbeke L, Gerris J. Equine estrogen-dydrogesterone therapy in the management of postmenopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol. 23: 201, 1986.

    Article  PubMed  Google Scholar 

  13. Hargrove J.T., Maxson W.S., Colston Wentz A., Burnett L.S. Menopausal hormone replacement therapy with continuos daily oral micronized estradiol and progesterone. Obstet. Gynecol. 73: 606, 1989.

    PubMed  CAS  Google Scholar 

  14. L’Hermite M. Risk of estrogens and progestogens. Maturitas 12: 215, 1990.

    Article  PubMed  Google Scholar 

  15. Jensen J., Riis B.J., Christiansen K. Long term effects of percutaneous estrogen and oral progesterone on serum lipoprotein in postmenopausal women. Am. J. Obstet. Gynecol. 156: 166, 1987.

    Article  Google Scholar 

  16. Hirvonen E., Malkonen M., Manninen V. Effects of different progestogens on lipoprotein during postmenopausal replacement therapy. N. Engl. J. Med. 304: 560, 1981.

    Article  PubMed  CAS  Google Scholar 

  17. Williams S.R., Frenchek B., Speroff T., Speroff L. A study of combined continous ethinyestradiol and norethindroneacetate for postmenopausal hormone replacement. Am. J. Obstet. Gynecol. 162: 438, 1990.

    Article  PubMed  CAS  Google Scholar 

  18. Horowitz M., Wishart J.M., Need A., Morris H.A., Nordin C. Effects of norethisterone on bone related biochemical variables and forearm bone mineral in postmenopausal osteoporosis. Clin. Endocrinol. (Oxf.) 193: 649, 1993.

    Article  Google Scholar 

  19. Abdall H.I., McKay Hart D., Lindsay R., Leggate I., Hooke A. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet. Gynecol. 66: 789, 1985.

    Google Scholar 

  20. De Aloysio D., Mauloni M., Bottiglioni F. II climaterio femminile. Monduzzi Ed., Bologna, 1988, p. 363.

  21. Bengtsson C, Lindquist O. Menopausal effects on risk factors for ischemic heart disease. Maturitas 1: 165, 1978.

    Article  Google Scholar 

  22. Ginsburg J., Swinhoe J., O’Reilly B. Cardiovascular responses during the menopausal hot flush. Br. J. Obstet. Gynecol. 88: 925, 1981.

    Article  CAS  Google Scholar 

  23. Prough S.G., Aksel S., Weibe R.H., Shepherd J. Continuos estrogen/progestin therapy in menopause. Am. J. Obstet. Gynecol. 157: 1449, 1987.

    Article  PubMed  CAS  Google Scholar 

  24. Hemminki E., Tofo P., Malin M., Kangas I. Physicians views on hormone therapy around and after menopause. Maturitas 16: 163, 1993.

    Article  PubMed  CAS  Google Scholar 

  25. Marchesoni D., Baggio G., Pigozzo S., Mozzanega B. Variazioni indotte nel metabolismo dei lipidi da un trattamento sequenziale con estrogeni e progestinico in menopausa. In: Zichella L., Perrone G. (Eds.), Terza età della donna — Prevenzione e terapia in climaterio. Monduzzi Ed., Bologna, 1989, p. 487.

    Google Scholar 

  26. Mozzanega B., Marchesoni D., Lazzaro A.R., Simioni P., Girolami A. Complesso protrombinico e fattore VIII nella menopausa récente: effetti del medrossiproges-terone acetato in monoterapia ed in associazione sequenziale con gli estrogeni. In: Bottiglioni F., De Aloysio D. (Eds.) Il climaterio femminile: esperienze italiane di un decennio. Monduzzi Ed., Bologna, 1988 p. 557.

    Google Scholar 

  27. Whitehead M.I., Fraser D., Schenkel L., Crook D., Stevenson J.C. Transdermal administration of oestrogen/progestogen hormone replacement therapy. Lancet 335: 310, 1990.

    Article  PubMed  CAS  Google Scholar 

  28. Notelovitz M., Kitchens C.S., Ware M.D., Hirschberg K., Coone L. Combination estrogen and progestogen replacement therapy does not adversely affect coagulation. Obstet. Gynecol. 62: 596, 1983.

    PubMed  CAS  Google Scholar 

  29. Haffner S.M., Valdez R.A. Endogenous sex hormones: impact on lipids, lipoprotein, and insulin. Am. J. Med. 98(Suppl. A): 40S, 1995.

  30. Soma M.R., Osnago-Gadda I., Paoletti R., Fumagalli R., Morrisett J.D., Meschia M., Crosignani P.G. The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch. Intern. Med. 153: 1462, 1993.

    Article  PubMed  CAS  Google Scholar 

  31. The writing group from the PEPI trial. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273: 199, 1995.

    Article  Google Scholar 

  32. Psaty B.M., Heckbert S.H. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch. Intern. Med. 154: 1333, 1994.

    Article  PubMed  CAS  Google Scholar 

  33. Nabulsi A.A., Folsom A.R. Association of hormone-replacement therapy with cardiovascular risk factors in postmenopausal women. N. Engl. J. Med. 328: 1069, 1993.

    Article  PubMed  CAS  Google Scholar 

  34. Stampfer M.J., Colditz G.A., Willet W.C. Postmenopausal estrogen therapy and cardiovascular disease. N. Engl. J. Med. 325: 756, 1991.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marchesoni, D., Dal Pozzo, M., Dal Magro, L. et al. Transdermal estroprogestins versus transdermal estrogen plus oral dihydrogesterone replacement in menopause. J Endocrinol Invest 19, 268–272 (1996). https://doi.org/10.1007/BF03347862

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347862

Key-words

Navigation